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myocyte hypertrophy,2 alterations in LV myocardial
collagen content, and normalized expression of genes
involved with excitation-contraction coupling.3 Collec-
tively, these changes have been referred to as reverse
remodeling1 and, in some circumstances, lead to
improved intrinsic myocyte strength.3,4 In a small num-
ber of cases, the reverse remodeling leads to recovery of
chamber strength of sufficient magnitude to permit
LVAD explantation without the need for transplanta-
tion.5-7 Although clinical outcomes after LVAD explant
have not been uniformly good6 and LVAD explant is not
routine in the United States, understanding the process
of reverse remodeling is important. Such understanding
L eft ventricular assist devices (LVADs) are used as abridge to transplantation for patients with severe
decompensated heart failure. It has been demonstrated
that the pressure and volume unloading of the left ven-
tricle provided by LVADs can lead to normalization of
left ventricular (LV) geometry,1 regression of LV
Background: Support with a left ventricular assist device leads to normaliza-
tion of left ventricular chamber geometry, regression of myocyte hypertro-
phy, alterations in left ventricular collagen content, and normalized expres-
sion of genes involved with excitation-contraction coupling in patients with
heart failure. The objective of this study was to investigate the time course of
these processes.
Methods: Passive left ventricular pressure-volume relationships were
obtained from explanted hearts of 19 patients with heart failure undergoing
transplantation without left ventricular assist device support, 25 patients with
heart failure supported before transplantation (duration of support ranging
between 8 and 155 days), and 5 normal human hearts not suitable for trans-
plantation. Left ventricular size was indexed by the volume at which left ven-
tricular pressure reached 30 mm Hg. Left ventricular tissue samples were
probed for sarcoplasmic endoreticular calcium adenosine triphosphatase 2a
expression and processed for analysis of myocyte diameter and relative
myocardial collagen content.
Results: The volume at which left ventricular pressure reached 30 mm Hg
was not significantly different between hearts without and with assist device
support for less than 40 days. However, the volume at which left ventricular
pressure reached 30 mm Hg in patients with assist devices supported for
more than 40 days was significantly smaller than that of the hearts without
assist devices but was larger than that of normal hearts. A similar pattern was
observed for myocyte diameter. Sarcoplasmic endoreticular calcium adeno-
sine triphosphatase 2a expression increased to normal levels by about 20
days of support with an assist device. Relative collagen content was signifi-
cantly increased in hearts supported for more than 40 days.
Conclusion: Maximum structural reverse remodeling by left ventricular assist
devices is complete by about 40 days. Molecular reverse remodeling of sar-
coplasmic endoreticular calcium adenosine triphosphatase 2a expression is
quicker, being complete by about 20 days. (J Thorac Cardiovasc Surg
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will lead to new insights into fundamental mechanisms
underlying heart failure, the extent to which patho-
physiologic processes can be reversed, and the poten-
tial role of LVAD therapy as an adjunct to other thera-
pies aimed at curing heart failure. More recent evidence
suggesting that long-term outcome after LVAD explan-
tation could be improved with appropriate patient
selection and weaning protocols7 make improved
understanding of the process even more important.
Current understanding of LVAD-induced reverse
remodeling is rudimentary. One fundamental unex-
plored aspect of this multifaceted process is the time
course with which it occurs. The objective of this study
was therefore to define the time course of structural,
cellular, interstitial, and molecular reverse remodeling
of the left ventricle during LVAD support.
Methods
Heart harvest and pressure-volume relationships.
Under a protocol approved by the Institutional Review Board
of the Columbia Presbyterian Medical Center, 49 human
hearts were used for this study. Hearts from 19 patients with
end-stage congestive heart failure (CHF) and 25 patients with
end-stage CHF supported by a Thermo Cardiosystems, Inc
(TCI, Woburn, Mass) LVAD for varying amounts of time
were obtained at the time of cardiac transplantation. Five nor-
mal donor hearts unsuitable for transplantation were also
obtained.
All hearts were perfused with cold, hypocalcemic, hyper-
kalemic cardioplegic solution at explantation. The passive LV
pressure-volume relationship of each arrested heart was mea-
sured as described previously.3 In brief, the aortic root and, in
the case of the LVAD-supported hearts, the LVAD inflow can-
nula were clamp occluded. A metal adapter was attached to
the mitral anulus, and a compliant water-filled latex balloon
was placed within the LV chamber. Pressure within the bal-
loon was measured with a high-fidelity micromanometer as
volume was progressively increased. The pressure was then
plotted as a function of volume at each step, resulting in a
passive LV pressure-volume relationship that is similar to the
end-diastolic pressure-volume relationship of a contracting
heart. Chamber size was indexed by the volume at which
pressure within the ventricle reached 30 mm Hg (LVV30).
Myocyte diameter and myocardial collagen content.
Tissue samples were obtained from the LV free wall, fixed in
10% buffered formalin, embedded in paraffin, and mounted
on glass slides. Samples were then prepared with Masson
trichrome stain. Images were viewed on a Nikon microscope
(Nikon Corporation, Tokyo, Japan) with an MTI 3CCD digi-
tal camera (Dage-MTI, Inc, Michigan City, Ind) at 20× mag-
nification to assess myocyte diameter and at 4× magnification
to assess myocardial collagen content. Digitally acquired
images were analyzed with Image Pro Plus V3.0 software
(Media Cybernetics, LP, Silver Spring, Md) by an examiner
blinded to whether the heart was normal, failing, or LVAD
supported. Two orthogonal diameters were obtained per
myocyte and then averaged. Only sections containing fibers
cut in cross-section were analyzed. The diameters of 50
myocytes per patient were measured and then averaged.
Myocardial collagen content was assessed by using a green
software filter. On each section, a density range was set to
resemble the collagen content. The number of pixels includ-
ed in this range was divided by the total number of pixels on
the fields. Ten fields at 4× magnification per patient were ana-
lyzed, and results were then averaged.
Northern blot analysis. Tissue samples were obtained
from the LV free wall and snap-frozen in liquid nitrogen for
RNA extraction. Total RNA was extracted from the myocar-
dial tissue samples with guanidinium thiocyanate followed
by centrifugation in cesium chloride solutions. Aliquots (25
µg) of total RNA quantified by absorbance at 260 nm were
then separated by using electrophoresis in 1% agarose/15%
formaldehyde gels in 1× 3-(N-morpholino) propanesulfonic
acid buffer (Fisher Scientific, Hampton, NJ). After intensive
capillary transfer to Nirto Pure nitrocellulose membranes
(MSI, Westboro, Mass) in 20× standard saline citrate (SSC;
1× SSC equals 3 mol/L sodium chloride and 0.15 mol/L
sodium citrate, pH 7.0), the RNA was fixed by baking in a
vacuum oven at 80°C for 1 hour and prehybridized at 42°C
for more than 3 hours in a solution of 50% formamide, 4×
Table I. Patient demographics
Parameter Non-LVAD LVAD (all)* LVAD0-40* LVAD40+*
No. 19 25 6 19
Cause (ICM/DCM/other) 9/10/0 8/14/3 2/4/0 6/10/3
Age (y) 51.5 ± 12.9 52 ± 13 53.1 ± 5.5 51.5 ± 14.3
BSA (m2) 1.9 ± 0.2 1.9 ± 0.2 2.1 ± 0.3 1.8 ± 0.1
EF (%) 18 ± 4 18 ± 5 16 ± 7 18 ± 4
LV EDD (cm) 6.9 ± 0.6 7.2 ± 1.3 7.2 ± 1.3 6.9 ± 0.6
PCWP (mm Hg) 25 ± 10 27 ± 8 25 ± 13 25 ± 10
Duration of LVAD support NA 88 ± 44 21 ± 11 100 ± 33
ICM, Ischemic cardiomyopathy; DCM, dilated idiopathic cardiomyopathy; BSA, body surface area; EF, ejection fraction; EDD, end-diastolic diameter; PCWP, pul-
monary capillary wedge pressure; NA, not applicable.
*All values for patients with LVADs are those at the time of LVAD implantation, whereas values for the non-LVAD patients are those at the time of transplantation.
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SSC, 1× Denhardt solution, 0.1% sodium dodecylsulfate
(SDS), 1 mmol/L ethylenediaminetetraacetic acid, and 0.125
mg/mL denatured salmon testis DNA. The blots were
hybridized overnight with cDNA for rat sarcoplasmic
endoreticular calcium adenosine triphosphatase 2
(SERCA2; 1.181-kb EcoRI fragment, a generous gift from
Dr Gerd Hasenfuss) and human reduced glyceraldehyde-
phosphate dehydrogenase (GAPDH; 1.3-kb PstI fragment).
All cDNA probes were labeled with a phosphorus
32–labeled deoxycytidine triphosphate (3000 Ci/mmol,
Amersham, Arlington Heights, Ill) to a specific activity of 1
× 106 cpm/µg by using a multiprimer DNA-labeling system
(Amersham). The blots were washed twice in 2× SSC at
room temperature for 15 minutes and 3 times in 0.1×
SSC/0.1% SDS at 68°C for 15 minutes and exposed to X-
OMAT AR film (Eastman Kodak Company, Rochester, NY)
at –70°C with an intensifying screen for 48 to 72 hours.
Autoradiograms were then analyzed by means of laser den-
sitometry (Molecular Dynamics Inc, Sunnyvale, Calif) in
the linear response range of the x-ray films by using
GAPDH as an internal standard. The relative SERCA2a
expression was quantified as the ratio of SERCA2a band
intensity to GAPDH band intensity. To be able to pool
results from different gels, all values were further standard-
ized to the average intensities of the same 3 normal samples
that were included on every blot. Of the major proteins
involved in calcium cycling that we have examined previ-
ously (which have included the ryanodine receptor and
sodium-calcium exchanger in addition to SERCA2a), it is
our experience that SERCA2a mRNA levels are the highest
under normal conditions and thus provide the greatest relia-
bility for detecting changes in expression.3
Data analysis. Data related to each parameter examined
were graphed as a function of duration of LVAD support and
fit to an exponential function as follows:
y = y
o
+ α (1-e–t/τ)
where y is the parameter of interest, y
o
is the extrapolated
value to 0 days of support, t is the duration of LVAD support,
α is the maximum magnitude of the change, and τ is the time
constant for change. Fitting was done with a nonlinear
Levenberg-Marquard algorithm. To determine whether these
relationships where statistically significant, they were lin-
earized by means of a standard logarithmic transformation.
Linear regression analysis was then applied, which provided
a P value for the relationship.
As detailed further in the “Results” section, patients were
divided into 4 groups on the basis of duration of support for
the purpose of performing statistical comparisons. The nor-
mal group (n = 5) comprised hearts from normal donors. The
non-LVAD group (n = 19) comprised hearts from patients in
end-stage CHF who did not receive LVAD support before
transplantation. The LVAD0-40 group (n = 6) comprised hearts
from patients with end-stage CHF supported for less than 40
days before transplantation. The LVAD40+ group (n = 19)
comprised hearts from patients with end-stage CHF support-
ed for more than 40 days before transplantation. The choice
of 40 days as the cutoff point for this grouping was based on
the longest time constant of change determined from the non-
linear analysis. Differences between the groups were ana-
lyzed by means of 1-factor analysis of variance with a Tukey-
Kramer post hoc multiple comparisons test. All values are
presented as means and SDs.
Results
Patient population. Patient demographics are sum-
marized in Table I. The cause of CHF was similar in
the non-LVAD and LVAD groups, with slightly more
patients having dilated idiopathic cardiomyopathy
than ischemic cardiomyopathy. All patients with
LVADs were receiving inotropic and vasopressor ther-
apies before LVAD insertion. This was not generally
the case for patients in the non-LVAD group, some of
whom were living at home before transplantation.
Fig 1. A, Passive pressure-volume relationships for the 4
groups (squares, LVAD0-40; triangles, LVAD40+; diamonds,
non-LVAD; circles, normal). B, LVV30 versus duration of
LVAD support (squares, LVAD0-40; triangles, LVAD40+; dia-
monds, non-LVAD; circles, normal; dashed line, nonlinear fit
to LVAD data). See Table II for regression parameters.
A
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None of the patients required mechanical biventricu-
lar support before LVAD insertion or transplantation,
although several patients required support with intra-
aortic balloon counterpulsation. The mean duration of
LVAD support was 82 days and ranged between 8 and
155 days. There were no statistically significant dif-
ferences in preoperative body surface area, ejection
fraction, left ventricular end-diastolic dimension, or
pulmonary capillary wedge pressure between groups.
LVV30. The LVV30 value was plotted as a function of
the duration of LVAD support, as shown in Fig 1, B.
LVV30 decreased monotonically with increased duration
of LVAD support, indicating progressive reverse structur-
al remodeling of the chamber to a plateau value. LVV30
values of the patients in the non-LVAD group were simi-
lar to those in the LVAD group supported for short dura-
tions and were each significantly larger than LVV30 val-
ues of normal hearts. The nonlinear fit to the LVAD data
(parameter values summarized in Table II) revealed a time
constant of approximately 30 days. Statistical compar-
isons revealed no difference between LVV30 values of the
non-LVAD and LVAD0-40 groups (P = .14) and statistical-
ly significant differences between the non-LVAD and
LVAD40+ groups (P < .001) and LVAD0-40 and LVAD40+
Fig 2. Trichrome-stained sections of LV free wall demonstrating myocyte diameter for normal (A), non-LVAD (B),
and LVAD40+ (C) groups. (Original magnification 20×.) D, Myocyte diameter versus duration of LVAD support
(squares, LVAD0-40; triangles, LVAD40+; diamonds, non-LVAD; circles, normal; dashed line, nonlinear fit to LVAD
data). See Table II for regression parameters.
Table II. Parameter values for nonlinear time course of change in parameter values as a function of duration of
LVAD support: y = y
o
+ α (1-e–t/τ)
Parameter LVV30 Myocyte diameter Collagen content SERCA2 expression
y
o
217.7 0.141 –11.1 –1.26
α 140.5 0.262 17.98 0.902
τ 30.8 23.7 39.2 15.1
P value <.0001 <.0001 .0003 .0421
y
o
, Starting value was set at the mean value obtained from all non-LVAD transplanted hearts; α, amplitude of the change; τ, time constant of change. P values are the
statistical significance of the relationship between time and the specified variable.
groups (P < .001) and between the control group and each
of the other 3 groups (P = .015). Thus although substantial
chamber reverse remodeling had occurred with LVAD
durations greater than 40 days, LVV30 on average was
still greater than that of the normal hearts. These differ-
ences are shown more clearly in the mean passive pres-
sure-volume curves for the normal, non-LVAD, LVAD0-40,
and LVAD40+ hearts shown in Fig 1, A.
Myocyte diameter. The relationship between LV
myocyte diameter and duration of support is shown in
Fig 2, D (format similar to that of Fig 1, B). The time
constant of change of myocyte diameter was approxi-
mately 24 days. There was a significant difference
between the non-LVAD and normal groups (P < .001),
and no statistically significant difference between the
non-LVAD and LVAD0-40 groups (P = .18). The
LVAD40+ group exhibited significantly smaller diame-
ters when compared with the non-LVAD group 
(P = .002), although the values were still significantly
larger than those in the normal hearts (P = .01).
Examples of histologic samples are shown in Fig 2, A
(normal), B (LVAD0-40), and C (LVAD40+).
SERCA2a expression. Typical examples of
Northern blots obtained from these hearts are shown in
Fig 3, A. The relationship between LV myocardial
expression of SERCA2a expression and duration of
support is shown in Fig 3, B (format similar to that of
Fig 1, B). As in previous studies, SERCA2a expression
was significantly decreased in the non-LVAD patients
undergoing CHF and in the LVAD0-40 group compared
with the normal group (P < .001 and P = .005, respec-
tively), and there was no statistically significant differ-
ence between the non-LVAD and LVAD0-40 groups 
(P = .18). The LVAD40+ group, however, exhibited val-
ues significantly higher than those of the non-LVAD
group (P < .001) and reached values that were not dif-
ferent than those of the normal hearts (P = .30). The time
constant of change of SERCA2a determined by the non-
linear curve fitting was approximately 15 days, which is
shorter than those of the other parameters examined.
Myocardial collagen content. The relationship
between relative myocardial collagen content
(defined as the percentage of sample area occupied
by blue-staining collagen fibers on Trichrome-
stained slides) and duration of support is shown in
Fig 4, D (format similar to that of Fig 1, B). In con-
trast to the other parameters studied, there was no
statistically significant difference between the non-
LVAD and normal groups (P = .24). There was also
no statistically significant difference between the
non-LVAD and LVAD0-40 groups (P = .10). However,
the LVAD40+ group exhibited values significantly
higher than those of the non-LVAD group (P < .001).
The blinded nature of this analysis and the attempt to
avoid areas of massively fibrotic areas should be reit-
erated. The time constant of change of interstitial col-
lagen was about 40 days, which is slightly longer
than the other parameters. Subgroup analysis showed
that this finding was independent of the cause of CHF
(ischemic cardiomyopathy vs dilated idiopathic car-
diomyopathy). Thus LVAD support may lead to an
increase in relative myocardial collagen content.
Examples of histologic sample are shown in Fig 4, A
(normal), B (LVAD0-40), and C (LVAD40+).
Discussion
The present study confirms prior reports showing
that reverse remodeling, including decreased chamber
size, decreased myocyte size, and increased expression
of the gene encoding for SERCA2a (an important
enzyme pump involved in calcium cycling and excita-
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Fig 3. A, Typical northern blot demonstrating expression of
SERCA2a relative to the GAPDH reference gene. B,
Expression of SERCA2a versus duration of LVAD support
(squares, LVAD0-40; triangles, LVAD40+; diamonds, non-
LVAD; circles, normal; dashed line, nonlinear fit to LVAD
data). See Table II for regression parameters.
A
B
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tion contraction coupling) occurs during LVAD support
in a majority of patients, regardless of cause. The time
constant of change for these parameters ranged
between 15 and 30 days, and therefore the maximum
benefit was observed by approximately 40 days.
Structural aspects of reverse remodeling did not reach
complete normalization, although SERCA2a expres-
sion did normalize.
Relative collagen content increased during LVAD
support. It is likely that this is purely a result of the
decrease in myocyte mass that occurs during LVAD
support rather than increased deposition of collagen. It
is clear that a decrease in myocyte mass with a fixed
absolute amount of collagen would result in an increase
by the same percentage of myocardium occupied by
collagen. By using a simple model of myocardium
composed only of myocytes and collagen, it can be
shown quantitatively that a reduction of myocyte diam-
eter from 35 to 25 µm would be expected to increase
relative collagen content from the measured starting
value of 10% to a predicted value of 14% if the
absolute amount of collagen remained constant. This is
very close to the measured 15% collagen content deter-
mined for the LVAD40+ group by means of blinded
analysis (Fig 4, D). Additionally, the half-life of colla-
gen turnover is between 80 and 120 days, and therefore
the patients with LVADs included in the present study
did not have durations of support long enough to allow
for significant alterations in collagen deposition or
resorption. Significantly longer durations of support
would be required to determine whether LVAD support
influences absolute collagen content.
The precise mechanisms underlying the various
aspects of reverse remodeling remain to be determined.
The mechanisms underlying hypertrophy and chamber
remodeling in response to pressure and volume loading
of the myocardium involves intricately orchestrated
upregulation and downregulation of a multitude of
intracellular signaling cascades.8 Although investigated
for over 20 years, these mechanisms are still not fully
understood. It has been our working hypothesis that
reverse remodeling involves the same mechanisms
Fig 4. Trichrome-stained sections of LV free wall demonstrating relative myocardial collagen content for normal
(A), non-LVAD (B), and LVAD40+ (C) groups. (Original magnification 4×.) D, Relative myocardial collagen con-
tent versus duration of LVAD support (squares, LVAD0-40; triangles, LVAD40+; diamonds, non-LVAD; circles, nor-
mal; dashed line, nonlinear fit to LVAD data). See Table II for regression parameters.
after this time point. In the short term a small increase
in relative interstitial fibrosis may occur, not because of
an increase in collagen deposition but because of the
decrease in myocyte diameter with no significant
change in total collagen content.
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working in the opposite direction. In fact, it has been
questioned whether reverse remodeling is simply a
reflection of myocyte atrophy. The finding that, on
average, myocyte diameters in the LVAD40+ group
were still larger than normal and that the process of cel-
lular size reduction appears to be completed by approx-
imately 40 days despite continued off-loading of the
muscle implies that there is a limit to how much atro-
phy the once diseased and hypertrophied myocyte can
undergo.
Recent evidence suggests that in some patients,
LVAD support may lead to improvement of global
pump function of sufficient magnitude to permit
explantation of the device without subsequent trans-
plantation.5 This has led to the concept of using LVADs
as a bridge to recovery. The potential of this possibility
is strengthened by data demonstrating normalization of
LV chamber geometry,1 regression of LV myocyte
hypertrophy,2 increased myocyte contractile strength,
enhanced inotropic response to adrenergic stimulation,
and improved cytosolic calcium transients.4 However,
in a recent article from our institution, there was a low
incidence of myocardial recovery during LVAD sup-
port, as assessed by exercise testing with device output
turned down, and the outcome of a small group of
patients that underwent explantation was not uniform-
ly good.6 Accordingly, weaning from LVAD support is
not currently considered the standard of care, although
more recent data suggest that outcome after LVAD
explant may be improved.7 The goal of using LVADs as
a bridge to recovery is a worthy pursuit because of the
severe imbalance between the number of patients
requiring transplant and the number of available donor
hearts. Better understanding of the process of reverse
remodeling will aid the development of adjunctive
therapies, better patient selection criteria, and perhaps
optimum LVAD use protocols to improve patient out-
come after LVAD explantation. The data of the present
study indicate that, as used currently, maximum bene-
fits of LVADs in terms of reverse remodeling are
observed after about 40 days, and little change is seen
